Logo of Huzzle

Intern, Regulatory Affairs

Applications are closed

  • Internship
    Full-time
    Summer Internship
  • Science
  • San Francisco

Requirements

  • Required Skills:
  • Advanced knowledge of Microsoft Office Suite
  • Strong written communication and information synthesis skills
  • Knowledge of basic health sciences
  • Basic understanding of drug development pipeline
  • Desired Skills:
  • Enthusiasm to tackle and learn new projects
  • Qualitative and/or quantitative science background
  • Intermediate/advanced background in biology or related health sciences
  • Qualifications/Eligibility:
  • Bachelors degree in biology or related science field (Health Sciences, Epidemiology, Public Health, Health Research, etc.)
  • Student must be returning to school in the Fall Term OR has graduated within the 1 year of the start of the program.
  • Must be available to work 40 hours a week
  • Must be authorized to work in the United States without visa sponsorship

Responsibilities

  • Synthesizing/collating cross-functional Stakeholder insights to better characterize and coordinate messaging on unmet need, nonclinical data analysis, and clinical literature to support early drug development in targeted patient populations to gain skills in information synthesis and global regulatory strategic planning.
  • Supporting the global regulatory team during dynamic and fast paced global regulatory health authority filings including but not limited to preparation and submissions.
  • Working closely with cross-functional Stakeholders to develop strategic messaging and documentation supporting worldwide health authority interactions.

We transform lives through genetic discovery.

Science & Healthcare
Industry
1001-5000
Employees
1997
Founded Year

Mission & Purpose

Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple product candidates applying the same science-driven, patient-forward approach to broader group of genetic disorders. The more innovative solutions developed, the more lives BioMarin can impact.